DE69103130T2 - Zellfreies Marekskrankheitvirus-Vakzin. - Google Patents

Zellfreies Marekskrankheitvirus-Vakzin.

Info

Publication number
DE69103130T2
DE69103130T2 DE69103130T DE69103130T DE69103130T2 DE 69103130 T2 DE69103130 T2 DE 69103130T2 DE 69103130 T DE69103130 T DE 69103130T DE 69103130 T DE69103130 T DE 69103130T DE 69103130 T2 DE69103130 T2 DE 69103130T2
Authority
DE
Germany
Prior art keywords
disease virus
cell
marek
virus vaccine
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE69103130T
Other languages
English (en)
Other versions
DE69103130D1 (de
Inventor
William Baxendale
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intervet International BV
Original Assignee
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8205666&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69103130(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo Nobel NV filed Critical Akzo Nobel NV
Application granted granted Critical
Publication of DE69103130D1 publication Critical patent/DE69103130D1/de
Publication of DE69103130T2 publication Critical patent/DE69103130T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/255—Marek's disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16361—Methods of inactivation or attenuation
    • C12N2710/16364—Methods of inactivation or attenuation by serial passage

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69103130T 1990-12-24 1991-12-20 Zellfreies Marekskrankheitvirus-Vakzin. Revoked DE69103130T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP90314297 1990-12-24

Publications (2)

Publication Number Publication Date
DE69103130D1 DE69103130D1 (de) 1994-09-01
DE69103130T2 true DE69103130T2 (de) 1994-12-01

Family

ID=8205666

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69103130T Revoked DE69103130T2 (de) 1990-12-24 1991-12-20 Zellfreies Marekskrankheitvirus-Vakzin.

Country Status (17)

Country Link
US (1) US5378467A (de)
EP (1) EP0496135B1 (de)
JP (1) JP3410744B2 (de)
KR (1) KR100187317B1 (de)
CN (1) CN1034554C (de)
AT (1) ATE109007T1 (de)
CA (1) CA2058386C (de)
DE (1) DE69103130T2 (de)
DK (1) DK0496135T3 (de)
DZ (1) DZ1550A1 (de)
ES (1) ES2061165T3 (de)
HU (2) HUT62200A (de)
IL (1) IL100386A (de)
MX (1) MX9102757A (de)
NZ (1) NZ241122A (de)
SA (1) SA92120430B1 (de)
ZA (1) ZA9110022B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023078A1 (en) * 1992-05-19 1993-11-25 Viktoria Alexeevna Lukina Vaccine for prophylaxis of marek disease of birds and method of its preparation
FR2719056B1 (fr) * 1994-04-20 1996-09-06 Rhone Merieux Herpesvirus transformés pour exprimer gD in vitro.
IL114501A (en) * 1994-07-14 1999-08-17 Akzo Nobel Nv Marek's disease virus vaccine
EP0703294A1 (de) * 1994-07-14 1996-03-27 Akzo Nobel N.V. Virusimpfstoff gegen Mareksche Krankheit
US5565202A (en) * 1994-08-12 1996-10-15 The United States Of America As Represented By The Secretary Of Agriculture Low enhancement serotype 2 vaccine for marek's disease
FR2857671B1 (fr) * 2003-07-18 2007-10-05 Centre Nat Rech Scient Nouveau procede de culture de keratinocytes et ses applications
ES2436317T3 (es) * 2010-05-07 2013-12-30 Deutsches Krebsforschungszentrum Parvovirus de roedor modificado capaz de propagarse y difundirse en gliomas humanos
CN111542337A (zh) 2017-12-20 2020-08-14 英特维特国际股份有限公司 用于细胞相关联的α疱疹病毒疫苗的改良稀释剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4160024A (en) * 1978-05-01 1979-07-03 Cornell Research Foundation, Inc. Marek's disease vaccine
US4895718A (en) * 1987-07-10 1990-01-23 The United States Of America, As Represented By The Secretary Of Agriculture Serotype 2 Marek's disease vaccine
JPS62212326A (ja) * 1987-09-14 1987-09-18 Gen Corp:Kk マレツク病２価生ワクチンとその製造方法

Also Published As

Publication number Publication date
MX9102757A (es) 1992-07-01
NZ241122A (en) 1992-10-28
ZA9110022B (en) 1992-10-28
SA92120430B1 (ar) 2004-05-31
ES2061165T3 (es) 1994-12-01
KR100187317B1 (ko) 1999-05-01
JPH04295433A (ja) 1992-10-20
IL100386A (en) 1995-07-31
EP0496135A2 (de) 1992-07-29
KR920011520A (ko) 1992-07-24
IL100386A0 (en) 1992-09-06
EP0496135B1 (de) 1994-07-27
DE69103130D1 (de) 1994-09-01
HUT62200A (en) 1993-04-28
HU914111D0 (en) 1992-03-30
DK0496135T3 (da) 1994-11-28
EP0496135A3 (de) 1992-08-05
US5378467A (en) 1995-01-03
ATE109007T1 (de) 1994-08-15
DZ1550A1 (fr) 2002-02-17
CA2058386C (en) 2003-02-11
CN1064409A (zh) 1992-09-16
CN1034554C (zh) 1997-04-16
JP3410744B2 (ja) 2003-05-26
HU210344A9 (en) 1995-04-28
CA2058386A1 (en) 1992-06-25

Similar Documents

Publication Publication Date Title
DE69016956D1 (de) Rekombinantes Truthahn-Herpesvirus und davon abgeleiteter Lebendimpfstoffvektor.
BR9102672A (pt) Composicao para exterminar microorganismos, composicao para exterminar virus envelopados, processo para exterminar microorganismos em ou sobre um hospedeiro e processo para exterminar virus envelopados em um ser humano ou animal de sangue quente, hospedeiro
MY103575A (en) Cannie coronavirus vaccine
DK0496135T3 (da) Cellefri Mareks sygdomsvirus-vaccine
IE780360L (en) Vaccine against "egg drop disease".
FI890116A0 (fi) Icke-reverterande rna-virus.
ATE86119T1 (de) Lebendvaccine fuer ansteckungskrankheiten von kueken.
WO1994000586A3 (fr) Mutants et vaccins du virus de la rhinotracheite infectieuse bovine
ATE59778T1 (de) Verwendung von sulfonamidderivaten zur herstellung eines antivirusmittels.
MX9602256A (es) Vacuna contra la enfermedad de marek.
NZ228232A (en) Live combined vaccine comprising at least one live infectious bronchitis virus and at least one other virus infectious to poultry
ES515472A0 (es) Procedimiento para proteger anfitriones susceptibles de infeccion de hepatitis.
ATE165620T1 (de) Impfstoffe auf basis geänderter boviner herpesviren typ 1
ATE3058T1 (de) Herpes-virus-impfstoff und seine herstellung.
TH12563EX (th) วีคซีนป้องกันไวรัสโรคมาเร็คชนิดปราศจากเซลล์
ATE310078T1 (de) Hühner-anäemie-virus mit geringer pathogenität
Paprocka Assessment of FMD virus propagation in cell culture system and inactivating preparations in order to obtain an effective vaccine.
ES2084587T3 (es) Arn virus no revertientes.
NO884921L (no) Fremgangsmaate for fremstilling av valpesyke-vaksine.

Legal Events

Date Code Title Description
8363 Opposition against the patent
8327 Change in the person/name/address of the patent owner

Owner name: INTERVET INTERNATIONAL B. V., AN BOXMEER, NL

8339 Ceased/non-payment of the annual fee
8331 Complete revocation
8380 Miscellaneous part iii

Free format text: DIE ZURUECKNAHME VOM 22.10.2009 WURDE GELOESCHT.